- Home
- AKBA vs SDHY Comparison
AKBA vs SDHY Comparison
Compare AKBA & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- SDHY
- Stock Information
- Founded
- AKBA 2007
- SDHY 2020
- Country
- AKBA United States
- SDHY United States
- Employees
- AKBA N/A
- SDHY N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- SDHY Finance/Investors Services
- Sector
- AKBA Health Care
- SDHY Finance
- Exchange
- AKBA Nasdaq
- SDHY Nasdaq
- Market Cap
- AKBA 336.2M
- SDHY 402.7M
- IPO Year
- AKBA 2014
- SDHY N/A
- Fundamental
- Price
- AKBA $1.93
- SDHY $16.21
- Analyst Decision
- AKBA Strong Buy
- SDHY
- Analyst Count
- AKBA 1
- SDHY 0
- Target Price
- AKBA $7.50
- SDHY N/A
- AVG Volume (30 Days)
- AKBA 2.1M
- SDHY 94.0K
- Earning Date
- AKBA 11-07-2024
- SDHY 01-01-0001
- Dividend Yield
- AKBA N/A
- SDHY 8.46%
- EPS Growth
- AKBA N/A
- SDHY N/A
- EPS
- AKBA N/A
- SDHY 1.07
- Revenue
- AKBA $169,879,000.00
- SDHY N/A
- Revenue This Year
- AKBA N/A
- SDHY N/A
- Revenue Next Year
- AKBA $30.85
- SDHY N/A
- P/E Ratio
- AKBA N/A
- SDHY $14.31
- Revenue Growth
- AKBA N/A
- SDHY N/A
- 52 Week Low
- AKBA $0.80
- SDHY $13.93
- 52 Week High
- AKBA $2.48
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- AKBA 54.91
- SDHY 37.39
- Support Level
- AKBA $1.74
- SDHY $16.11
- Resistance Level
- AKBA $1.90
- SDHY $16.33
- Average True Range (ATR)
- AKBA 0.08
- SDHY 0.13
- MACD
- AKBA -0.01
- SDHY -0.03
- Stochastic Oscillator
- AKBA 54.44
- SDHY 18.89
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.